Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals
Key facts
- Who runs it
- Swiss Paraplegic Research, Nottwil
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 50 people enrolled
- Started
- 13 Aug 2018
- Ended
- 31 Dec 2024
- Type of study
- Observational
- Treatments tested
- measurement of tumor mRNA concentration in urine
- Record updated
- 13 February 2025
- Why it stopped
- insufficient recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Symptoms suspicious of bladder cancer (haematuria, ultrasonic and cystoscopy findings)
- Chronic spinal cord injury for a minimum of 3 years
- Informed Consent as documented by signature
Who cannot take part
- Previous intravesical treatment (e.g. bladder irrigation, botulinum toxin injection) < 2 weeks)
- History of bleeding disorder
- Acute, symptomatic urinary tract infection
- Age < 18 years
- Bladder augmentation
- Pregnancy
- Urolithiasis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Bladder cancer is a well-recognized complication in spinal cord injury (SCI) individuals. The observed incidence rates in SCI individuals are considerably higher compared to the general population. Bladder cancer in SCI individuals tends to present at an earlier age compared to the general population. Furthermore, bladder cancer in SCI individuals is more commonly invasive and at a more advanced stage at the time of diagnosis compared to bladder cancer in the general population. Individuals with bladder cancer commonly present with hematuria and other urinary symptoms. The gold standard for diagnosis is cystoscopy. However in SCI individuals, hematuria may get attributed to catheter irritation or trauma or an urinary tract infection. Furthermore, the bladder wall commonly presents with various changes under cystoscopic examination masking the presence of a bladder wall mass. Thus, diagnosis of bladder cancer in SCI individuals can be complicate.
Read full original descriptionShow less
There is a novel test available (GeneXpert® Bladder Cancer Detection, Cepheid International, Sunnyvale, CA, USA) for the measurement of mRNA bladder tumor markers in the urine. The diagnostic accuracy of this test has been investigated in non-SCI individuals with symptoms suspicious for bladder cancer. The test showed high sensitivity and specificity values and is thus a promising diagnostic or screening tool.. However, the diagnostic accuracy of the test has not yet been investigated in SCI individuals.
The primary objective of the proposed study is to investigate whether urine mRNA tumor marker levels in spinal cord injury individuals with symptoms and findings suspicious for bladder cancer are a discriminator between individuals suffering from bladder cancer and those not suffering from cancer.
Individuals presenting with symptoms suspicious of bladder cancer will undergo ultrasonic and cystoscopic examination of the bladder. An urine sample will be taken, and the bladder will be flushed for collecting a bladder fluid sample. In patients with bladder wall findings suspicious of cancer, a bladder wall biopsy will be taken, according to clinical standard practice. The bladder fluid and the bladder wall biopsy will be submitted for cytology and histopathology examination, respectively. Tumor mRNA levels will be measured in the urine sample.
Treatments tested
- measurement of tumor mRNA concentration in urine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Quantitative Evaluation of a Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Individuals With Symptoms or Clinical Findings Suspicious for Bladder Cancer
- Record updated
- 13 February 2025